Cellular Engineering Technologies, Inc. (CET) is a leading biotechnology company with over a decade of human somatic and induced pluripotent stem cell manufacturing experience. Our portfolio includes human Mesenchymal stem cells, iPS cell lines, disease-specific iPS cell lines, growth and differentiation media, custom iPS reprogramming, and drug screening assay services.

CET specializes in stem cell research, tissue engineering and cancer biology. We manufacture specialized media and cell lines, and provide contractual research services with normal and patient-specific stem cells. CET is a leading provider of induced pluripotent stem (iPS) cells derived from normal human volunteers and patients with various clinical conditions. CET provides services in preclinical drug discovery and clinical research services.